arsenic trioxide
information and resources from the National Cancer Institute
arsenic trioxide
A small-molecule arsenic compound with antineoplastic activity. The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic.arsenic trioxide
A small-molecule arsenic compound with antineoplastic activity. The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic.
Trisenox
Second line treatment of relapsed or refractory APL following ATRA plus an anthracycline.
Cell Therapeutic Sep 25 2000
|
|
|
|
news articles
Arsenic Trioxide Effective as Single Agent in Newly Diagnosed APL Mar 31, 2006
Cancer Consultants (press release), According to an article recently published in the journal Blood, the agent arsenic trioxide, when used as a single agent, provides impressive outcomes among ...
Single-Agent Arsenic Trioxide Very Effective for Treatment of APL Mar 27, 2006
Cancer Consultants (press release), Researchers from India have reported that single-agent arsenic trioxide (ATO), without ATRA (all-trans retinoic acid) and combination chemotherapy, results in ...
Cephalon Granted Six Months of Pediatric Exclusivity for PROVIGIL Mar 28, 2006
PharmaLive.com (press release), GABITRIL(R) (tiagabine hydrochloride) Tablets, ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], and TRISENOX(R) (arsenic trioxide) injection, and numerous ...
FDA Advisory Committee Recommends Against Approval of SPARLON(TM) ... Mar 23, 2006
Yahoo! News (press release) PROVIGIL, GABITRIL® (tiagabine hydrochloride) Tablets, ACTIQ® (oral transmucosal fentanyl citrate) [C-II], and TRISENOX® (arsenic trioxide) injection, and ...
Recycled Or Revamped Therapeutics Find Novel Anti-cancer ... Nov 20, 2005
Science Daily (press release) ...not a common item in health food stores, but organic arsenic appears to be a whole lot better as an anti-cancer drug than its inorganic cousin, arsenic trioxide ...
Cephalon to Webcast Dec. 19, 2005 Investor Meeting Dec 19, 2005
PharmaLive.com (press release), ...modafinil) [C-IV], GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II] and TRISENOX(R) (arsenic trioxide) injection and ...
Arsenic removed at Quitman Dec 15, 2005
Heber Springs Sun-Times, ...“This arsenic contains Arsenic Trioxide, Arsenic Pentoxide, and Arsenic Metallic,� he said. “That makes this 70-percent active.�. ...
ZIOPHARM Oncology Announces ZIO-101 Data Published in Blood Nov 21, 2005
Business Wire (press release), In this study, the cytotoxic properties and mechanism of action of ZIO-101 were compared to arsenic trioxide (ATO) in four multiple myeloma cell lines. ...
Cephalon Oncology Reports High Response Rates to Single Agent ... Dec 12, 2005
PR Newswire (press release), The Cephalon Oncology portfolio includes three lead compounds to treat patients with hematologic cancers: from TRISENOX(R) (arsenic trioxide) injection, an ...
Scientific Advances on Three Lead Cephalon Oncology Compounds to ... Dec 8, 2005
PR Newswire (press release), At ASH, researchers also will report data from investigator- sponsored studies of TRISENOX(R) (arsenic trioxide) injection, the company's marketed anti-cancer ...
Scientific Advances on Three Lead Cephalon Oncology Compounds to ... Dec 8, 2005
Yahoo! News (press release) At ASH, researchers also will report data from investigator- sponsored studies of TRISENOX® (arsenic trioxide) injection, the company's marketed anti-cancer ...
Cephalon, Inc. Announces Agreement to Acquire Zeneus Holdings ... Dec 5, 2005
PR Newswire UK (press release), C-IV], GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II] and TRISENOX(R) (arsenic trioxide) injection, and more than ...
Ziopharm's anticancer drug shows potential Nov 18, 2005
Pharmaceutical Business Review ...a novel organic arsenic, has demonstrated safety at doses approximately 25 times higher than the currently approved dose for arsenic trioxide, an inorganic ...
Source: Cephalon, Inc.; Zeneus Holdings Limited Dec 5, 2005
Yahoo! News (press release) ...modafinil) [C-IV], GABITRIL® (tiagabine hydrochloride), ACTIQ® (oral transmucosal fentanyl citrate) [C-II] and TRISENOX® (arsenic trioxide) injection, and ...
|
|
